The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study-Reference-Cited by-同舟云学术

The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study

Published:2022-04 Issue:2 Volume:7 Page:100415
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Izawa N.,Shiokawa H.,Onuki R.,Hamaji K.,Morikawa K.,Saji H.,Ohashi H.,Kasugai S.,Hayakawa N.,Ohara T.,Sunakawa Y.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab;Menzies;Ann Oncol,2017

2. Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer;Toi;JAMA Oncol,2019

3. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab;Kimbara;Cancer Sci,2018

4. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC;Matsuura;Cancer Immunol Immunother,2018

5. Detection of various platelet-associated immunoglobulins by flow cytometry in idiopathic thrombocytopenic purpura;Nishioka;Cytometry B Clin Cytom,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival;Frontiers in Endocrinology;2024-04-12

2. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20

3. Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-01-05

4. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs);OncoImmunology;2023-05-11